Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Comment: avoiding detrimental effects of corticosteroids on JC virus T-cell responses--primum non nocere.

Koralnik IJ, Clifford DB.

Neurology. 2012 Dec 4;79(23):2263. doi: 10.1212/WNL.0b013e3182768a21. Epub 2012 Nov 21. No abstract available.

PMID:
23175725
2.

Author Response.

Du Pasquier RA, Canales M, Schluep M.

Neurology. 2013 Jul 2;81(1):98. No abstract available.

PMID:
23980272
3.

Impairment of JCV-specific T-cell response by corticotherapy: effect on PML-IRIS management?

Zahednasab H.

Neurology. 2013 Jul 2;81(1):97-8. doi: 10.1212/01.wnl.0000432104.96450.bc. No abstract available.

PMID:
23817518
4.

Impairment of JCV-specific T-cell response by corticotherapy: effect on PML-IRIS management?

Antoniol C, Jilek S, Schluep M, Mercier N, Canales M, Le Goff G, Campiche C, Pantaleo G, Du Pasquier RA.

Neurology. 2012 Dec 4;79(23):2258-64. doi: 10.1212/WNL.0b013e3182768983. Epub 2012 Nov 21.

PMID:
23175722
5.

No evidence of JC virus reactivation in natalizumab treated multiple sclerosis patients: an 18 month follow-up study.

Rinaldi L, Rinaldi F, Perini P, Calabrese M, Seppi D, Grossi P, Mattisi I, Barzon L, Mengoli C, Sanzari M, Palú G, Gallo P.

J Neurol Neurosurg Psychiatry. 2010 Dec;81(12):1345-50. doi: 10.1136/jnnp.2009.201079. Epub 2010 Jun 14.

PMID:
20547618
6.

Reply to "'Thinking without thinking' about natalizumab and PML".

Houff S, Berger JR.

J Neurol Sci. 2008 Jan 15;264(1-2):198-9; author reply 199. Epub 2007 Oct 15. No abstract available.

PMID:
17936798
7.

Risk of natalizumab-associated progressive multifocal leukoencephalopathy.

Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, Lee S, Plavina T, Scanlon JV, Sandrock A, Bozic C.

N Engl J Med. 2012 May 17;366(20):1870-80. doi: 10.1056/NEJMoa1107829.

8.

Central role of JC virus-specific CD4+ lymphocytes in progressive multi-focal leucoencephalopathy-immune reconstitution inflammatory syndrome.

Aly L, Yousef S, Schippling S, Jelcic I, Breiden P, Matschke J, Schulz R, Bofill-Mas S, Jones L, Demina V, Linnebank M, Ogg G, Girones R, Weber T, Sospedra M, Martin R.

Brain. 2011 Sep;134(Pt 9):2687-702. doi: 10.1093/brain/awr206.

PMID:
21908874
9.

IVIg attenuates T cell-mediated killing of human neurons.

Janke AD, Giuliani F, Yong VW.

J Neuroimmunol. 2006 Aug;177(1-2):181-8.

PMID:
16766045
10.

T-cell subsets in the cerebrospinal fluid and peripheral blood of multiple sclerosis patients treated with high-dose intravenous methylprednisolone.

Frequin ST, Lamers KJ, Borm GF, Barkhof F, Jongen PJ, Hommes OR.

Acta Neurol Scand. 1993 Aug;88(2):80-6.

PMID:
8213063
11.

Effect of cyclophosphamide and methylprednisolone on in vitro cellular immune response to allogeneic tumor cells. Correlation with in vivo rejection.

Gerber M, Andress D, Pioch Y, Radal M, Serrou B.

Transplantation. 1978 Sep;26(3):142-9. No abstract available.

PMID:
309196
12.

Clinical study on CXCL13, CCL17, CCL20 and IL-17 as immune cell migration navigators in relapsing-remitting multiple sclerosis patients.

Kalinowska-Łyszczarz A, Szczuciński A, Pawlak MA, Losy J.

J Neurol Sci. 2011 Jan 15;300(1-2):81-5. doi: 10.1016/j.jns.2010.09.026. Epub 2010 Oct 13.

PMID:
20947098
13.

Cellular immunity after intravenous administration of methylprednisolone.

Webel ML, Ritts RE Jr, Taswell HF, Danadio JV Jr, Woods JE.

J Lab Clin Med. 1974 Mar;83(3):383-92. No abstract available.

PMID:
4272969
14.

Natalizumab-associated progressive multifocal leukoencephalopathy.

Mancini N, Clementi M, Burioni R.

N Engl J Med. 2012 Aug 30;367(9):871-2; author reply 872. doi: 10.1056/NEJMc1207116#SA2. No abstract available.

PMID:
22931329
15.

Natalizumab-associated progressive multifocal leukoencephalopathy.

Cervera C.

N Engl J Med. 2012 Aug 30;367(9):871; author reply 872. doi: 10.1056/NEJMc1207116#SA1. No abstract available.

PMID:
22931328
16.

Predicting risk of progressive multifocal leukoencephalopathy from natalizumab.

Ropper AH.

N Engl J Med. 2012 May 17;366(20):1938-9. doi: 10.1056/NEJMe1201395. No abstract available. Erratum in: N Engl J Med. 2012 Jul 5;367(1):93.

PMID:
22591300
17.

[Risk stratification of progressive multifocal leukoencephalopathy under natalizumab: recommendations for JC virus serology].

Warnke C, Adams O, Hartung HP, Gold R, Hemmer B, Hohlfeld R, Stangel M, Zipp F, Wiendl H, Kieseier BC.

Nervenarzt. 2011 Oct;82(10):1314-9. doi: 10.1007/s00115-011-3319-2. German. No abstract available.

PMID:
21656322
19.

Natalizumab-associated PML identified in the presymptomatic phase using MRI surveillance.

Blair NF, Brew BJ, Halpern JP.

Neurology. 2012 Feb 14;78(7):507-8. doi: 10.1212/WNL.0b013e318246d6d8. Epub 2012 Feb 1. No abstract available.

PMID:
22302545
20.

[Introduction to the clinical use of immunosuppressive agents].

Bach JF.

Ann Med Interne (Paris). 1974 Oct;125(10):697-702. French. No abstract available.

PMID:
4548812

Supplemental Content

Support Center